ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke
In VivoLaNova Medicines founder, chairwoman, and CEO Crystal Qin credits China’s “remarkable transformation and significantly evolved health care system” for her company’s rapid success. Under her leadership
ScripSichuan Kelun Pharmaceutical has won an approval in China for its Merck & Co.-partnered sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate (ADC), which becomes the world’
ScripOnce a key part of its next-generation plans in cancer, Merck & Co . has called a halt to the last remaining Phase III studies of its TIGIT- and LAG-3 targeting immunotherapy assets. The two immu